Cita APA (7a ed.)
Hamilton, E. P., Patel, M. R., Borges, V. F., Meisel, J. L., Okera, M., Alemany, C. A., . . . Lin, N. U. (2025). Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: Phase 1/2 study results. Breast Cancer Research. https://doi.org/10.1186/s13058-025-02049-y
Cita Chicago Style (17a ed.)
Hamilton, Erika P., et al. "Palazestrant, a Novel Oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in Patients with ER+/HER2− advanced or Metastatic Breast Cancer: Phase 1/2 Study Results." Breast Cancer Research 2025. https://doi.org/10.1186/s13058-025-02049-y.
Cita MLA (9a ed.)
Hamilton, Erika P., et al. "Palazestrant, a Novel Oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in Patients with ER+/HER2− advanced or Metastatic Breast Cancer: Phase 1/2 Study Results." Breast Cancer Research, 2025, https://doi.org/10.1186/s13058-025-02049-y.
Precaución: Estas citas no son 100% exactas.